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Na+/Ca2+/Li+ exchanger upregulation
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Abstract
Variants of leucine-rich repeat kinase 2 (lrrk2) are associated with an increased risk in developing Parkinson’s disease
(PD). Mitochondrial dysfunction and specifically mitochondrial Ca2+ handling has been linked to the pathogenesis of
PD. Here we describe for the second time a mitochondrial Ca2+ efflux deficiency in a model displaying alterations in a
PD-associated risk protein. LRRK2 deletion, inhibition and mutations led to an impaired mitochondrial Ca2+ extrusion
via Na+/Ca2+/Li+ exchanger (NCLX) which in turn lowered mitochondrial permeability transition pore (PTP) opening
threshold and increased cell death. The mitochondrial membrane potential was found not to be the underlying cause
for the Ca2+ extrusion deficiency. NCLX activity was rescued by a direct (phosphomimetic NCLX mutant) and indirect
(protein kinase A) activation which in turn elevated the PTP opening threshold. Therefore, at least two PD-associated
risk protein pathways appear to converge on NCLX controlling mitochondrial Ca2+ extrusion and therefore
mitochondrial health. Since mitochondrial Ca2+ overload has been described in many neurological disorders this
study warrants further studies into NCLX as a potential therapeutic target.
Introduction
Parkinson’s disease is a common, disabling, incurable
neurodegenerative condition affecting 1% of the popula-
tion over the age of 60. The past 10 years have seen a shift
in the aetiological understanding of PD, moving from a
nearly exclusively environmentally mediated disease
towards a complex disorder with important genetic con-
tributions1. One of the most extensively studied genes
containing these mutations is the leucine-rich repeat
kinase 2. In particular, the missense mutation G2019S has
been reported to be the underlying cause for PD in 1–2%
in the UK/USA rising to 10% in Ashkenazi Jews and 40%
in North African Arab Berbers2,3. LRRK2 possesses a
kinase and a ROC-GTPase domain whose exact physio-
logical function is yet to be fully unravelled but studies
provided evidence for a role of LRRK2 in vesicle traf-
ficking, inflammatory responses, autophagy and neurite
outgrowth4–7; with few phosphorylation substrates iden-
tified8,9. The multitude of pathways regulated by LRRK2
demonstrate the complexity of LRRK2 mutations and
their potential effects on cellular signalling pathways. In
PD, it has long been known that LRRK2 mutations (in
particular G2019S) lead to an increased kinase activity
and this upregulation is currently being targeted by
LRRK2 kinase inhibitors as a therapeutic agent in PD10–12.
Mitochondrial dysfunction is strongly implicated in PD
as toxic models of PD which employ mitochondrial toxins
as well as the majority of proteins associated with familial
forms of PD affect mitochondrial function. Recently,
we have shown how another PD-associated protein,
PINK1, is involved in mitochondrial Ca2+ homoeostasis
suggesting a potential role for the recently described
sodium Ca2+ exchanger (NCLX) in PD pathology13–15.
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While mitochondrial Ca2+ shuttling couples between
Ca2+ signalling and metabolic activity, its impairment
can lead to mitochondrial Ca2+ overload that can be a
trigger for neuronal cell death. We have shown that the
mitochondrial Ca2+ overload phenotype in PINK1 defi-
cient cells can be rescued by a PKA/NCLX-mediated
pathway16. Furthermore, α-synuclein has been linked to
Ca2+-induced cell death17,18 suggesting that inhibition of
mitochondrial Ca2+ efflux may be a common feature in
the mechanism of neurodegeneration observed in PD. To
test this hypothesis, we used LRRK2 deficient cells and
assessed mitochondrial Ca2+ homoeostasis.
This current study established that mitochondrial Ca2+
homoeostasis is a common phenotype in PD and not
specific to PINK1 deficiency only.
Methods
Animals
Wild-type and LRRK2 KO mice were obtained from
breeding colonies generated by Jackson Laboratories and
Sprague Dawley rat pups (1–3 days postpartum) were
acquired from the University College London breeding
colony. Wild-type rat of either sex were used for neuronal
co-cultures and experimental procedures were performed
in full compliance with the United Kingdom Animal
(Scientific Procedures) Act of 1986.
Cell culture
Mixed cultures of cortical and midbrain neurons and
glial cells were prepared from postnatal pups (Control/
LRRK2 KO mice or rats; day 0–3; UCL breeding colony).
Midbrain were removed and placed into ice-cold
Ca2+/Mg2+ free PBS (Invitrogen, UK). The tissue was
minced and trypsinised (0.25%; 5 min at 37 °C), triturated
and plated on poly-D-lysine-coated coverslips. The tissue
was cultured in Neurobasal A medium (Invitrogen, UK)
supplemented with B-27 (Invitrogen, Paisley, UK) and 2
mM GlutaMAX (Invitrogen, UK)19. Cultures were main-
tained at 37 °C in a humidified atmosphere of 5% CO2 and
95% air; media was changed twice weekly and maintained
for a minimum of 12 days before experimental use to
ensure expression of glutamatergic and other receptors.
Only neurons were used for analysis. Neurons were dis-
tinguishable from glia: they appeared phase bright, had
smooth rounded somata and distinct processes, and lay
just above the focal plane of the glial layer. Cells were used
at 12–15 days in vitro. Experimental procedures were
performed in full compliance with the United Kingdom
Animal (Scientific Procedures) Act of 1986.
Fibroblasts were generated from a skin punch biopsy
taken under local anaesthetic following local ethical
approval and full informed consent20. Biopsies were dis-
sected into ~1mm pieces and cultured in DMEM, 10%
FBS, 1% GlutaMAX until fibroblasts were seen to grow
out from the explants. When fibroblasts reached con-
fluency, they were detached from culture dishes using
TrypleE (Invitrogen) and transferred to larger culture
vessels for further expansion and cryopreservation.
Plasmids and transfection
Preparation of human WT NCLX plasmids and site-
directed mutagenesis was carried out as previously
described16,21. Plasmids were transfected using Effectene
(Qiagen) according to manufacturers protocol. NCLX
plasmids were co-transfected with an empty GFP vector
(pcDNA3 backbone) to allow for selection of transfected
cells for experimentation and analysis.
Live-cell imaging
For cytosolic Ca2+ imaging, cells were loaded for 30 min
with 0.005% Pluronic and the Ca2+ indicator Fluo-4 AM
(Kd ~ 350 nM; 5 µM). Mitochondrial Ca
2+ was visualised
by pre-loading cells with 0.005% Pluronic and either
Rhod5N AM (Kd ~ 19 µM; 5 µM) or Rhod-2 AM (Kd ~
700 nM; 5 µM) for 20min. Whole-cell imaging was car-
ried out in a HEPES-buffered salt solution (HBSS). Cells
were loaded for 30 min with 0.005% Pluronic and CoroNa
green AM (Kd ~ 80mM; 5 µM) to visualise Na
+.
For TMRM experiments, cells were placed in a HBSS
containing 25 nM TMRM for 40min at room tempera-
ture. TMRM was excited using the 560 nm laser line and
fluorescence was measured > 580 nm using a Zeiss 710
VIS CLSM equipped with a META detection system and a
×40 oil-immersion objective. Z-stack images were
obtained by confocal microscopy and the basal Δψm was
measured using Zen software (Zeiss).
Mitochondrial Ca2+ efflux was assessed in permeabi-
lized cells. To permeabilize, a buffer (0.137M NaCl, 5 mM
KCl, 0.7 mM NaH2PO4, 25 mM Tris-HCl, pH 7.1) con-
taining low concentration of digitonin (20 μM) was added
to the cells. Upon permeabilization, the buffer and digi-
tonin were replaced by fresh buffer containing mito-
chondrial substrates (5 mM glutamate and 5mM malate).
Cells were allowed to rest for at least 5 min before mea-
surements were taken. 20 μM CaCl2 was applied to assess
mitochondrial Ca2+ handling. Confocal images were
obtained using a Zeiss 710 equipped with a META
detection system and a ×40 oil-immersion objective.
Mitochondrial Ca2+ measurements were undertaken
using the 543 nm laser line and 560 nm longpass filter. A
488 nm Argon laser line was used to excite Fluo-4 which
was measured between 510 and 550 nm. The pinhole set
to give an optical slice of ~ 2 μm and illumination inten-
sity was kept to a minimum (at 0.1–0.2% of laser output)
to avoid phototoxicity.
PTP opening threshold was determined with increasing
concentrations of the electrogenic Ca2+ ionophore fer-
utinin in stepwise fashion22. Briefly, ferutinin induces a
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rise in mitochondrial calcium and the concentration of
ferutinin required to induce PTP opening (confirmed by
the rapid loss of TMRM signal) was determined.
Cell toxicity experiment
Cells were incubated with propidium iodide (PI; 20 μM)
and Hoechst 33342 (4.5 µM; Molecular Probes, Eugene,
OR). Viable cells exclude the red fluorescent PI whereas
Hoechst stains chromatin blue in all cells thus allowing
dead cells to be quantified.
Statistical analysis
Statistical analysis and exponential curve fitting were
performed using Origin 9 software. Experimental data are
shown as means ± SEM. Statistical analysis between
samples was performed using a one-way ANOVA with
Bonferroni correction. Differences were considered to be
significantly different if p < 0.05.
Results
Ca2+ dysregulation in LRRK2 KO primary cultures
First we assessed whether deletion of LRRK2 leads to a
dysregulation in Ca2+ homeostasis. To do so, we used
primary neuron/glia co-cultures from the cerebral cor-
tex/midbrain of wild-type (WT) and LRRK2 knockout
(KO) mice. Both cytosolic and mitochondrial Ca2+ was
assessed upon adenosine triphosphate (ATP) applica-
tion. Intracellular Ca2+ levels are tightly controlled by
the ER which is the main Ca2+ store and mitochondria
which “fine-tunes” Ca2+ transients. Exogenous applied
ATP triggers an intracellular Ca2+ release from the
endoplasmic reticulum (ER) via P2Y receptors followed
by activation of the phospholipase C and IP3 pathway in
astrocytes23. The Ca2+ release from the ER into the
cytosol leads to a simultaneous increase in mitochon-
drial Ca2+. Application of ATP led to increased cytosolic
and mitochondrial Ca2+ in WT astrocytes and Ca2+
levels recovered back to basal levels typically within 1
min (Fig. 1a). However, it was noted that after a short
recovery mitochondrial Ca2+ levels in KO astrocytes
induced a delayed calcium deregulation in form of a
secondary Ca2+ increase. The underlying reason could
be induced by opening of store-operated calcium
channels or energy deprivation followed by mitochon-
drial Ca2+ uptake24.
Altered mitochondrial Ca2+ efflux in LRRK2 deficient cells
Next, we investigated the underlying reason for the
observed inhibited mitochondrial Ca2+ efflux. Midbrain
WT and KO neurons were permeabilized and mito-
chondrial Ca2+ buffering was assessed by application
of exogenous CaCl2. Ca
2+ was taken up by the mito-
chondria and the rate of mitochondrial Ca2+ efflux
was significantly lower (0.19 ± 0.04; p < 0.001) in KO
mitochondria when compared with WT (0.4 ± 0.03;
Fig. 1b, c). The same effect was observed in cortical cells.
Figure 1d exemplifies that normalised mitochondrial
Ca2+ mirror non-normalised data. The maximal mito-
chondrial Ca2+ uptake was not significantly different in
KO neurons when compared with WT neurons indi-
cating that the slower Ca2+ efflux is not caused by an
increased Ca2+ uptake (Fig. 1e).
In excitable cells, mitochondrial Ca2+ is predominantly
removed by the sodium/Ca2+/lithium exchanger (NCLX)
and, to a lesser extent, by other efflux pathways. NCLX
translocates Na+ and Ca2+ ions across the inner mito-
chondrial membrane which can be visualised by loading
cells with CoroNA (Na2+ indicator) as well as xRhod1
(mitochondrial Ca2+ indicator). In permeabilized WT
neurons, application of CaCl2 resulted in an increase in
mitochondrial Ca2+ and decrease in mitochondrial Na+,
before Ca2+ is extruded and Na+ is taken up by the
mitochondria (Fig. 1f). However, in KO neurons, NCLX-
mediated mitochondrial Ca2+ extrusion is impaired sug-
gesting an altered NCLX activity leading to the inhibited
mitochondrial Ca2+ efflux.
Inhibition of kinase activity (loss of function) was
employed to confirm the mitochondrial Ca2+ efflux defi-
ciency is a LRRK2 mediated impairment. Therefore, two
LRRK2 kinase inhibitors were employed to assess whether
mitochondrial Ca2+ is a direct consequence of LRRK2
deficiency. To do so, WT rat primary neuron/glia co-
cultures were exposed to either LRRK2 inhibitor 1
(LRRK-IN-1; 1 µM), CZC-25146 (5 µM) or DMSO vehicle
control and mitochondrial Ca2+ homoeostasis was
assessed in neurons. Inhibition of LRRK2 kinase mirrored
the significant inhibited mitochondrial Ca2+ efflux
observed in KO mitochondria (Fig. 1g, h; p < 0.001). As a
positive control, the NCLX inhibitor CGP 37157 (10 µM)
was employed which mirrored the significantly inhibited
mitochondrial Ca2+ efflux similar to that observed in
LRRK2 deficient models (Fig. 1g, h; 0.05 ± 0.01; p < 0.001).
Figure 1i shows that maximal mitochondrial Ca2+ uptake
was not significantly different when compared with con-
trol. Further, non-normalised data mirror the normalised
efflux data.
Fibroblast from PD patients bearing LRRK2 mutations
were employed to investigate whether this mitochon-
drial phenotype can also be observed in LRRK2-
associated PD, mirroring the PINK1 phenotype. Fibro-
blast from patients bearing either LRRK2 G2019S
(kinase domain), R1441G (ROC domain) or Y1699C
(COR domain) mutation and unaffected controls were
employed to assess whether mitochondrial Ca2+ buf-
fering was a common phenotype in PD as well as LRRK2
deficiencies. Indeed, the mitochondrial Ca2+ efflux was
significantly inhibited in G2019S (Fig. 1j, k; 0.14 ± 0.015;
p < 0.001), R1441G (0.21 ± 0.03; p < 0.001; n= 3
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Fig. 1 (See legend on next page.)
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experiments) and Y1699C (0.22 ± 0.02; p < 0.001) when
compared with the three matched control cell lines
(0.36 ± 0.02; 0.39 ± 0.02; 0.44 ± 0.03; Fig. 1j, k). Maximal
mitochondrial Ca2+ uptake was not significantly differ-
ent between cell types (Fig. 1l)
PD-associated mutations result in lower mitochondrial
Ca2+ handling capacity
The observed altered mitochondrial Ca2+ efflux defi-
ciency is likely to lower the mitochondrial Ca2+ buffering
capacity. To test this, we employed a natural electrogenic
Ca2+ ionophore ferutinin to promote mitochondrial Ca2+
overload independently of MCU and trigger Ca2+-
dependent PTP opening22,25. PTP opening can be visua-
lised by a significant drop in ΔΨm (Fig. 2a). Ferutinin was
applied and the PTP in LRRK2 mutation bearing fibro-
blasts opened at significantly lower ferutinin concentra-
tions. At 20 μM 62% of control cells ( ± 5.1%; p < 0.001;
Fig. 2b) depolarised, whereas 94% (G2019S), 100%
(R1441G) and 99% (Y1699C) were found to be depo-
larised. These results indicate that these LRRK2 muta-
tions lead to a significantly lower Ca2+ buffering capacity
when compared with control which may lead to an
increased bioenergetic imbalance in cells with a high-
energy demand such as neurons.
Mitochondrial Ca2+ efflux deficiency not due to lower
mitochondrial membrane potential
Mitochondrial Ca2+ homoeostasis is tightly linked to
mitochondrial membrane potential (ΔΨm) where an
altered potential could lead to the observed inhibited
mitochondrial Ca2+ efflux in LRRK2 deficiency. There-
fore, we assessed ΔΨm in LRRK2 KO, LRRK2 inhibitor
treated neuronal co-cultures and LRRK2 mutation bear-
ing fibroblasts (Fig. 3). A significantly higher ΔΨm was
recorded in LRRK2 KO neurons (116 ± 2.8%; p < 0.001)
and astrocytes (146 ± 5.1%; p < 0.001) when compared
with WT (Fig. 3a). Inhibition of LRRK2 with LRRK2-IN-1
and CZC-25146 resulted in a significantly increased ΔΨm
in neurons (158 ± 3.6% and 145 ± 6.3%, respectively; p <
0.001) and astrocytes (122 ± 7.6% and 115 ± 4.5%,
respectively; p < 0.05) when compared with cultures
treated with DMSO vehicle control (Fig. 3b, c). Analysis of
fibroblast bearing disease related LRRK2 mutations did
not reveal a significant difference in ΔΨm to matched
control fibroblasts (Fig. 3d).
Upregulation of NCLX rescues the inhibited mitochondrial
Ca2+ efflux
We have previously shown16 that direct and indirect
modulation of NCLX activity can rescue a deficient
(see figure on previous page)
Fig. 1 Altered Ca2+ homoeostasis in LRRK2 deficient cells. a Representative traces of either whole cell WT or LRRK2 KO primary astrocytes
stimulated with ATP. b Representative traces of permeabilized, CaCl2 stimulated WT and LRRK2 KO neurons. c Quantification of mitochondrial Ca
2+
efflux in WT and LRRK2 neurons (N= 3 experiments; n ≥ 45 cells). d Non-normalised mitochondrial Ca2+ efflux data mirror normalised mitochondrial
Ca2+ efflux data (c). e Quantification of maximum mitochondrial Ca2+ influx in permeabilised WT and KO neurons (N= 3 experiments; n ≥ 45 cells).
f Representative traces of sodium (CoroNA) and Ca2+ (xRhod1) in permeabilized, Ca2+-stimulated WT or LRRK2 KO neurons visualising Na+ and Ca2+
exchange. g Representative traces of permeabilized, CaCl2 stimulated WT rat neurons pre-treated with vehicle control, LRRK2-IN-1, CZC-25146 or
NCLX inhibitor (CGP 37157). h Quantification of mitochondrial Ca2+ efflux in DMSO, CZC-25146, LRRK2-IN-1 or CGP37157 treated WT rat neurons (N
= 3 experiments; n ≥ 39 cells). i Quantification of maximum mitochondrial Ca2+ uptake in permeabilised rat primary neurons treated with DMSO,
LRRK2 or NCLX inhibitors (N= 3 experiments; n ≥ 39 cells). j Representative traces of permeabilized, CaCl2 stimulated human control and G2019S,
R1441G or Y1699C fibroblasts. k Quantification of mitochondrial Ca2+ efflux in human control and LRRK2 mutation bearing fibroblasts.
l Quantification of maximum mitochondrial Ca2+ uptake in permeabilised fibroblasts (N= 3 experiments; n ≥ 42 cells). ***p < 0.001
Fig. 2 PD-associated mutations lower mitochondrial Ca2+ handling capacity. a Representative TMRM traces of control and mutant fibroblast in
response to ferutinin. Ferutinin was added in a stepwise fashion at concentrations indicated in the graph. Upon full PTP opening, a steep drop in
TMRM fluorescence was observed. The mitochondrial uncoupler FCCP was added as a positive control for mitochondrial uncoupling.
b Quantification of PTP opening in control and mutant fibroblast in response to 20 μM ferutinin with and without forskolin (N= 4 experiments; n ≥
59 cells). *p < 0.05; **p < 0.01; ***p < 0.001
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mitochondrial Ca2+ efflux. Therefore, this study tested
whether activation of NCLX is able to overcome the
mitochondrial Ca2+ efflux phenotype observed in LRRK2
deficient models.
Direct upregulation of NCLX is achieved by expression
of a constitutively active NCLX. We have previously
reported that the phosphomimetic mutant of NCLX
(NCLXS258D) prevents mitochondrial Ca2+ overload in a
PINK1 deficient model16. Hence, this study expressed
NCLXS258D in LRRK2 KO primary cultures and mito-
chondrial Ca2+ was recorded in neurons. Expression of
NCLXS258D restored the efflux back to levels similar to
those observed in WT neurons (0.23 ± 0.02 and 0.2 ± 0.01,
respectively; p < 0.001; Fig. 4a). Furthermore, expression
of NCLXS258D in patient fibroblast bearing the G2019S
fibroblasts restored mitochondrial Ca2+ efflux back to
unaffected control levels (0.38 ± 0.02 and 0.36 ± 0.01,
respectively; p < 0.001; Fig. 4b).
An indirect upregulation of NCLX can be achieved
through pre-exposure to the PKA activator forskolin.
Forskolin activates adenylyl cyclase which in turn raises
cyclic AMP (cAMP) levels. cAMP is required for PKA
activation which in turn enables NCLX phosphorylation
and therefore NCLX activation. WT neuronal co-cultures
were pre-exposed to both LRRK2 inhibitors and forskolin
before mitochondrial Ca2+ efflux was assessed in neurons
(Fig. 4d). As previously observed, LRRK2-IN-1 (0.2 ± 0.01;
p < 0.001) and CZC-25146 (0.3 ± 0.2; p < 0.001) inhibits
mitochondrial Ca2+ efflux when compared with DMSO
vehicle control (0.46 ± 0.01; p < 0.001; Fig. 4e). PKA-
dependent upregulation of NCLX by application of for-
skolin restored the mitochondrial Ca2+ efflux deficiency
in neurons treated with either LRRK2-IN-1 (0.48 ± 0.03;
p < 0.001) or CZC-25146 (0.54 ± 0.01; p < 0.001).
Further, patient fibroblasts bearing the LRRK2 muta-
tions were pre-exposed to forskolin and mitochondrial
Ca2+ efflux was assessed. Forskolin restored the efflux rate
in G2019S (0.29 ± 0.03), R1441G (0.29 ± 0.02) and
Y1669C (0.31 ± 0.04) back to levels observed in unaffected
control cell line (0.3 ± 0.017; Fig. 4e, f).
Forskolin was also able to restore the Ca2+ handling
capacity in fibroblast bearing LRRK2 mutations upon
ferutinin application (Fig. 2b). A significantly lower per-
centage of cells bearing LRRK2 mutations opened PTP
when challenged with 20 μM ferutinin, whereas 66% of
G2019S cells (versus 94% without forskolin; p < 0.001),
58% of Y1699C cells (versus 100% without forskolin; p <
0.001) and 60% of R1441G cells (versus 94% without
Fig. 3 Ca2+ efflux deficiency not caused by lower MMP. a Quantification of MMP in WT and LRRK2 KO neurons (N= 3 experiments; n ≥ 60) and
astrocytes (N= 3 experiments; n ≥ 41). b Quantification of MMP in rat WT neuronal co-cultures treated with either vehicle control DMSO, LRRK2-IN-1
or CZC-25146 (N= 3 experiments; n ≥ 45 cells). c Representative images of neurons and astrocytes treated with vehicle control DMSO, LRRK2-IN-1 or
CZC-25146 and labelled with calcein blue and TMRM. d Quantification of MMP in control and LRRK2 mutation bearing fibroblasts (N= 3 experiments;
n ≥ 42 cells). ***p < 0.001
Ludtmann et al. Cell Death and Disease          (2019) 10:265 Page 6 of 10
Official journal of the Cell Death Differentiation Association
forskolin; p < 0.01; n= 4 experiments) opened PTP at this
forskolin concentration. Pre-incubation of control fibro-
blasts with forskolin also significantly increased the Ca2+
handling capacity in control 1 and control 3 cells (p <
0.05; Fig. 2b).
NCLX modulation rescues Ca2+-dependent cell death
Since inhibition of NCLX leads to a slower mitochon-
drial Ca2+ efflux we investigated whether the Ca2+
imbalance leads to neurotoxicity and ultimately cell death.
We incubated primary neuronal co-cultures with DMSO,
LRRK2-IN-1 or CZC-25146 and assessed neuronal cell
death after 12 h. LRRK2-IN-1 increased neuronal cell
death to 27.9% (± 3.8%) and CZC-25146 to 44.6% ( ± 2.6%)
when compared with basal cell death of 15.7% ( ± 2.3%;
Fig. 5). LRRK2 inhibition made neurons more prone to
dopamine-induced cell toxicity and incubation of mid-
brain cultures with 70 μM dopamine triggered cell death,
which was significantly higher in LRRK2 inhibited neu-
rons (LRRK2-IN-1 51.8 ± 7.4%; CZC-25146 55.3 ± 5.9%)
when compared with control (22.46 ± 2.9%). Since NCLX
modulation rescued mitochondrial Ca2+ efflux we inves-
tigated whether upregulation is able to rescue dopamine-
induced cell death. Indeed, expression of NCLXS258D
Fig. 4 Direct and indirect upregulation of NCLX rescues mitochondrial Ca2+ efflux in all LRRK2 deficient models a Quantification of
mitochondrial Ca2+ efflux rate in LRRK2 WT and KO primary neurons with or without NCLXD (N= 3 experiment; n ≥ 40 neurons). b Quantification of
mitochondrial Ca2+ efflux rate in control or G2019S mutation bearing fibroblasts with or without NCLXD (N= 3 experiments; n ≥ 31 cells).
c Representative traces of mitochondrial Ca2+ efflux in neurons treated with DMSO, LRRK2-IN-1 or CZC-25146+ pre-incubation with forskolin.
d Quantification of mitochondrial Ca2+ efflux in neurons treated with DMSO, LRRK2-IN-1 or CZC-25146+ pre-incubation with forskolin (N= 3
experiments; n ≥ 59 cells). e Representative traces of mitochondrial Ca2+ efflux in permeabilised control, G2019S and G2019S+ forskolin fibroblasts.
f Quantification of mitochondrial Ca2+ efflux in permeabilised controls, G2019S, R1441G or Y1699C fibroblasts+/− forskolin (N= 4 experiments; n ≥
59 cells). *p < 0.05; **p < 0.01 ***p < 0.001
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restored cell death in LRRK2 inhibited neurons back to
control cell death levels (LRRK2-IN-1 12.1 ± 1.9%; CZC-
25146 28.3 ± 5.9%).
Discussion
Mitochondrial dysfunction has been linked to both
familial and sporadic forms of PD. Several PD risk genes,
such as PINK-1, Parkin and DJ-1 have been associated
with mitochondrial pathogenesis observed in PD with a
key role in mitochondrial Ca2+ homoeostasis26–28. Mito-
chondrial Ca2+ overload has a direct effect on mito-
chondrial bioenergetics and lowers the threshold for PTP
opening leading to premature cell death29,30 and has
previously been demonstrated in loss-of-function, reces-
sively inherited mutations of PINK117,31.
In this present study, we show that modulation of
LRRK2 through deletion (KO), inhibition (de-phosphor-
ylation) or mutagenesis of LRRK2 alters the mitochon-
drial Ca2+ efflux; therefore linking another PD risk gene
to NCLX leading to decreased PTP opening threshold and
an increased dopamine-induced neuronal death (Figs. 1, 2,
5). LRRK2 has previously been associated with mito-
chondrial membranes but no direct interaction between
LRRK2 and NCLX could be confirmed in our previous
manuscript (supplementary data) and is therefore unlikely
to directly modulate NCLX Ca2+ efflux11,16,32.
We and other have previously described that a lower
ΔΨm can result in reduced NCLX Ca
2+ efflux16,17.
However, ΔΨm in all LRRK2 models employed in this
current study is either not changed (fibroblasts) or ele-
vated (inhibitor/KO) when compared with control con-
ditions suggesting that the ΔΨm is not the underlying
reason for the mitochondrial Ca2+ efflux deficiency
(Fig. 3). Papkovskaia et al.33 have previously reported that
fibroblasts bearing G2019S bear a lower ΔΨm. This cur-
rent study employed three matched control cell lines as
well as three mutations affecting different domains of
LRRK2 (ROC, COR and kinase domain) and could not
find any significant changes in the ΔΨm.
A global Ca2+ dysregulation can lead to mitochondrial
Ca2+ dysregulation, For example, Bedford et al.34 have
provided evidence that LRRK2 stimulates voltage-gated
Ca2+ channels, while the PD mutation G2019S leads to an
increased channel stimulation when compared with wild-
type LRRK2. Furthermore, LRRK2 has been proposed to
stimulate plasma membrane sodium/calcium exchanger
activity35 and nicotinic acid adenine dinucleotide phos-
phate receptors36. These reports provide evidence for a
global Ca2+ regulation through LRRK2 where mutations
can lead to a Ca2+ dysregulation affecting organelles and
cellular functions. Indeed, Verma et al.37 has shown that
mitochondrial Ca2+ contributes to dendrite injury in a
LRRK2 PD model. The authors have also reported tran-
scriptional upregulation the mitochondrial calcium uni-
porter and the mitochondrial calcium uptake 1 protein
leading to increased mitochondrial Ca2+ influx. Interest-
ingly, we did not observe an altered mitochondrial Ca2+
uptake in any of the models employed in this current
study indicating other driving factor(s) for the mito-
chondrial Ca2+ efflux pathology (Fig. 1e, i, l).
The exact mechanism through which LRRK2 acts upon
NCLX Ca2+ extrusion requires further investigation.
LRRK2 has previously been reported to interact with the
regulatory subunit of PKA, negatively regulating activity
during synaptogenesis38. While LRRK2 is predominantly
expressed in the cytosol, it has previously been suggested
to affect mitochondrial dynamics39,40, with few studies
providing evidence for a mitochondrial localisation11,33.
Our study has shown that mutations in LRRK2 phe-
nocopy pharmacological inhibition and knockout of
LRRK2 despite opposing reported effects (gain vs loss of
function)41,42. One possible explanation may be link
between LRRK2/Rab32 and PKA. It was shown that the
small GTPase Rab32 interacts with the N-terminal
armadillo repeat LRRK2. Rab32 itself has been reported
to act as a PKA anchoring protein localising PKA to
mitochondria and was shown to modulate mitochondrial
associated membranes and mitochondrial fission43,44.
How mutations or inhibition affect these interactions and
the consequences on mitochondrial Ca2+ are yet to be
unravelled. Therefore, the link between LRRK2/Rab32/
PKA and its role in mitochondrial health in relation to PD
requires further investigations.
We have previously shown that upregulation of NCLX
via a cAMP/PKA-dependent activation through the
application of forskolin rescues the mitochondrial Ca2+
Fig. 5 Protective effects of NCLX upregulation from dopamine-
induced neuronal cell death. LRRK2 inhibitor treated neuronal
cultures were challenged with 70 μM Dopamine for 12 h and cell
death was assessed using PI and Hoechst (N= 3 experiments; each
data point represents one field of view with an average of 58
neurons). *p < 0.05; **p < 0.01
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efflux in PINK1 deficient models16. In this current study
expression of the constitutively active phosphomimetic
mutant of NCLX (NCLXS258D) also rescued the mito-
chondrial Ca2+ efflux in LRRK2 mutation bearing fibro-
blast and LRRK2 inhibitor treated cells in a similar
manner previously described in a PINK PD model16,45
(Fig. 3). We and others have previously shown that
cAMP-mediated PKA activation using forskolin reverses
pathologies in a PINK1 and LRRK2 G2019S PD
model16,46. This was mirrored in this current study as
application of forskolin (indirect NCLX upregulation)
restored the Ca2+ buffering capacity back to control levels
in LRRK2 mutation bearing fibroblasts (Fig. 2). Delayed
mitochondrial Ca2+ efflux, as described in this study, can
lead to mitochondrial swelling and a lowered PTP open-
ing threshold. PTP opening can be either triggered by
high Ca2+ levels and or high superoxide levels and is
characterised by the loss of the mitochondrial membrane
potential, swelling of the mitochondrial matrix, rupture of
the outer membrane and release of internalised Ca2+ and
pro-apoptotic proteins including cytochrome C. There-
fore, opening of the PTP is the first trigger for the
induction of cell death pathways (apoptosis and necrosis)
which can have particular detrimental effects in cells with
a high-energy demand such as dopaminergic neurons
which are predominantly affected in PD45,47. Here, we
have shown that LRRK2 inhibitors make neurons more
prone to dopamine-induced cell death (Ca2+-dependent).
By upregulation of NCLX and therefore enhancing
mitochondrial Ca2+ efflux, we were able to rescue this
dopamine-induced neuronal cell death (Fig. 5).
Inhibition of NCLX in midbrain neurons in LRRK2
mutation is specifically important because it enhances the
mitochondrial calcium level that increase probability to
open permeability transition pore in mitochondria and
trigger cell death in response to additional stresses which
are typical for PD pathology such as oligomeric α-
synuclein and dopamine48,49.
This study provides evidence that mitochondrial Ca2+
efflux deficiency is a common phenotype observed in two
PD-associated risk genes (PINK1 and LRRK2). This phe-
notype can be rescued by an upregulation of NCLX via a
direct or indirect cAMP/PKA-dependent approach which
may offer a novel therapeutic strategy in PD. The
observed phenotype associated with LRRK2 modulation
may be of particular importance when employing LRRK2
inhibitors as mitochondrial bioenergetics are likely to be
negatively affected. Prolonged mitochondrial Ca2+ dys-
regulation has detrimental bioenergetic consequences and
is of particular importance to high-energy-demanding
cells such as neurons. Since mitochondrial Ca2+ dysre-
gulation is a common phenotype in many neurodegen-
erative disease models NCLX and its regulators may serve
as a novel therapeutic strategy.
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